DNA-based therapeutics developer EnGene raised the money in a Pharmstandard-backed series B round that increased its overall funding to more than $31m.
Canada-based EnGene, a biotechnology company focused on delivering therapeutics for patients’ intestines, has secured $11.5m in a series B round that included pharmaceutical company Pharmstandard International.
The round also featured Merck Lumira Biosciences Fund, a Québec-focused biotechnology fund set up by pharmaceutical company Merck.
Forbion Capital Partners, a spin-out of Netherlands state-owned bank ABN Amro, led the round, while Lumira Capital, Teralys Capital and Fonds de solidarité FTQ, a development capital fund in Québec, also participated.
Merck Biosciences Fund previously…
